The survival time in lung cancer patients with pleural fluid IL-17 concentrations below 15 pg/ml was significantly longer than in those with higher concentrations (OS 10.8 vs. 4.7 months; P < 0.05) (Figure 3). This evidence concerns the gene IL17A and lung carcinoma.